Biologic Drugs in Development

August 02, 2020

Many antibody-drug conjugate therapies are in the pipeline; only a handful have been approved. What are the bottlenecks?

July 21, 2020

Preliminary data from a German Phase I/II trial shows Pfizer/BioNTech COVID-19 vaccine candidate produces immune response.

July 21, 2020

Study reports immune and T-cell response from CanSino COVID-19 vaccine candidate.

July 20, 2020

Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.

July 08, 2020

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.

July 08, 2020

BARDA and DOD have awarded a $450-million contract to Regeneron Pharmaceuticals to manufacture and supply an investigational double antibody cocktail in development for treating COVID-19.

July 02, 2020

BioPharm International

RNA is easier to manipulate than DNA but challenging to deliver to the right cells.

July 01, 2020

BioPharm International

Data and science must guide FDA in making pressure-filled COVID-19 vaccine and therapy approval decisions.

July 01, 2020

The complete response letter was issued for a biologics license application for Abicipar pegol, an investigational treatment for wet age-related macular degeneration, based on FDA’s determination of an unfavorable benefit–risk ratio.

June 11, 2020

The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.